Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid Cancer
During a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.
Progress in Treating RAI-Refractory DTC
Real-World Insight: Lenvatinib for RAI-Refractory DTC
Lenvatinib Data for RAI-Refractory DTC
Systemic Therapy for RAI-Refractory DTC
Recommendations for Treating Patients With DTC
Case Impressions: A 73-Year-Old Woman With DTC
A 73-Year-Old Woman With Differentiated Thyroid Cancer
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.